China’s Asieris Bets On Bladder Cancer With Rediscovered Asset From Johns Hopkins
Executive Summary
Emerging Company Profile: Aiming to change the current practice of surgically removing the bladder, China Asieris hopes to use an older drug to treat early-onset bladder cancer. This is the fourth and last in a series of China-based Emerging Company Profiles.
You may also be interested in...
Hot And Hotter: Lepu Takes $140m Leap Into China Immuno-Oncology Fray
Established just a year ago, China's Lepu Biotech has raised a mighty $131m to develop immuno-oncology antibodies, while Shanghai-based Asieris has obtained worldwide rights to develop and commercialize Photocure's Cevira for cervical dysplasia.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.